Table 2.
Drug | Clinicaltrials.gov Identifier | Site | Phase | Sponsor |
---|---|---|---|---|
Biomarker Study | NCT01130584 | Salivary levels of PKM2 | Observational | National University Hospital, Singapore |
TT-232 | NCT00422786 | Renal Cell Carcinoma | II | Thallion Pharmaceuticals |
TT-232 | NCT00735332 | Melanoma | II | Thallion Pharmaceuticals |
EZN-2968 | NCT00466583 | Carcinoma/Lymphoma | I | Enzon Pharmaceuticals, Inc. |
EZN-2968 | NCT01120288 | Neoplasms/Liver Metastases | I | National Cancer Institute (Luciani, et al.) |
PX-478 | NCT00522652 | Advanced solid tumors/Lymphoma | I | Oncothyreon Inc. |
AQ4N | NCT00394628 | Glioblastoma multiforme | Ib/IIa | Novacea |
AQ4N | NCT00109356 | Lymphoma/Leukemia | I/II | Novacea |
AQ4N | NCT00090727 | Solid tumors/Non-Hodgkin’s Lymphoma | I | Novacea |
Table describes clinical trials mentioned in review. Additional trials can be found at www.clinicaltrials.gov.